Background The treatment landscape for multiple myeloma (MM) has progressed
significantly, and over the past decade, bortezomib-based induction therapy has been a …

Background The aim of this study is to identify risk factors associated with the development
of severe bacterial infection (SBI) in patient with multiple myeloma (MM) during treatment …

Infections are an important cause of morbidity and mortality in newly diagnosed multiple
myeloma (NDMM), but the real-world risk using modern induction regimens such as …

The aim of this study was to identify the risk factors associated with severe bacterial infection
(SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens …

Fluoroquinolone is recommended as a prophylactic antibiotic for high-risk patients with
profound neutropenia. We previously reported that multiple myeloma (MM) patients who …

Abstract 5042 Bortezomib is a proteasome inhibitor with potent antimyeloma activity in
relapsed/refractory multiple myeloma (MM) patients. We evaluated the type and factors …

Background. Infections represent a major cause of toxicity in newly diagnosed multiple
myeloma (NDMM) patients, and their incidence is higher during the first 4 months of therapy …

Bortezomib is a proteasome inhibitor with potent antimyeloma activity in relapsed/refractory
multiple myeloma (MM) patients. We evaluated the types and factors affecting the onset of …

Introduction. Multiple myeloma (MM) represents a population with an increased risk of
developing infection up to 10-fold if compared with controls. Moreover, patients treated with …

Multiple myeloma (MM) is a malignancy of clonal plasma cells, resulting in an increased
production of ineffective immunoglobulins with suppression of non-involved …